Global Sales of 6 Major Recombinant Branded Products of Coagulation Factors VIII, IX & VIIa Reached USD 7.2 Billion in 2012, Says La Merie Publishing

10 Jun 2013 • by Natalie Aster

Global sales of the six major recombinant branded products of coagulation factors VIII, IX and VIIa in 2012 were US$ 7.2 bln. This attractive market size and the soon beginning expiration of basic patents stimulated established hemophilia product companies as well as companies with new technologies to enter the race for next generation systemic coagulation factor products. Projects hvae rapidly progressed in clinical trials and several of them are already under regulatory review.

Apart from recombinant products, plasma-derived coagulation factors still play a considerable role, albeit bovine derived products are considerably being challenged by human recombinant and human plasma-derived products. Coagulation factors not only are being used for systemic treatment of hereditary coagulation factor deficiencies, but also for topical or systemic treatment of bleedings.

A competitor analysis of plasma-derived and recombinant coagulation factors for topical or systemic administration to treat hereditary or acquired coagulation disorders as of May 2013 is available in the report “Competitor Analysis: Coagulation Factors” by La Merie Publishing.

Report Details:

Competitor Analysis: Coagulation Factors
Published: May, 2013
Pages: 158
Price: US$ 800.00

The report includes a compilation of current active projects in research and development of topical and systemic coagulation factors obtained by purification of human plasma or by recombinant DNA technology. In addition, the report lists company-specific product portoflios and R&D pipelines of coagulation factors. Competitor projects are listed in a tabular format providing information on:

• Drug Codes, 
• Target / Mechanism of Action, 
• Class of Compound, 
• Company, 
• Product Category, 
• Indication, 
• R&D Stage and 
• additional comments with a hyperlink leading to the source of information.

More information can be found in the report “Competitor Analysis: Coagulation Factors” by La Merie Publishing.

To order the report or ask for sample pages contact [email protected]

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com